Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabis Extract in Oncology Patients for Tumor Related Symptom Burden
NCT07459920Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Avextra 10/10 in advanced malignant solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoint: Edmonton Symptom Assessment System Total Symptom Distress Score at 52 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Avextra 10/10
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT07459920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459920.